Comprehensive ReviewExtensive-Stage Small-Cell Lung Cancer: Evolution of Systemic Therapy and Future Directions
References (146)
- et al.
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Lancet Oncol
(2006) FDA approves sorafenib for patients with inoperable liver cancer
Gastroenterology
(2008)- et al.
Renal cell carcinoma: current status and emerging therapies
Cancer Treat Rev
(2007) - et al.
Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens
Eur J Cancer
(2003) - et al.
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
J Thorac Oncol
(2007) - et al.
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
Ann Oncol
(2004) - et al.
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial
Lung Cancer
(2006) - et al.
Expression of bcl-2–protein in small cell lung cancer
Lung Cancer
(1996) - et al.
Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC
Eur J Cancer
(1994) - et al.
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a phase III trial of the Hellenic Oncology Research Group
Clin Lung Cancer
(2005)
Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. ‘Petites Cellules’ Group
Lung Cancer
(1999)
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
Ann Oncol
(2001)
A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party
Ann Oncol
(1990)
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
J Thromb Haemost
(2004)
A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
Lung Cancer
(2006)
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119
J Thorac Oncol
(2007)
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group
Lung Cancer
(2007)
Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study
Ann Oncol
(2001)
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
J Thorac Oncol
(2007)
A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer
Lung Cancer
(2004)
Single-agent gemcitabine in patients with resistant small-cell lung cancer
Ann Oncol
(2001)
Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer
J Clin Oncol
(2003)
The proteasome: a suitable antineoplastic target
Nat Rev Cancer
(2004)
The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial
J Clin Oncl
(2005)
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition
Cancer Res
(2001)
[Web site]. Bortezomib and topotecan in treating patients with advanced solid tumors
Quantitative distribution of cluster 1 small cell lung cancer antigen in cancerous and non-cancerous tissues, cultured cells and sera
Jpn J Cancer Res
(1989)
Phase II Trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma
J Clin Oncol
(2005)
[Web site]. Weekly dosing with BB-10901 in patients with small cell lung cancer
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
Clin Cancer Res
(2006)
[Web site]. Vaccine therapy and chemotherapy with or without tretinoin in treating patients with extensive-stage small cell lung cancer
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
N Engl J Med
(2002)
Systemic therapy for metastatic colorectal cancer: current options, current evidence
J Clin Oncol
(2005)
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
Cancer Res
(2005)
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01
J Clin Oncol
(2007)
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20
J Clin Oncol
(2007)
Autocrine and paracrine signaling through neuropeptide receptors in human cancer
Oncogene
(2001)
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103
J Clin Oncol
(2008)
Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients
Intern Med
(2005)
High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
Int J Cancer
(1998)
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
Proc Natl Acad Sci U S A
(2002)
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
Clin Cancer Res
(2000)
Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor
Cancer Res
(1996)
Phase II study of imatinib in patients with small cell lung cancer
Clin Cancer Res
(2003)
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance
Clin Cancer Res
(2004)
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
Mol Cancer
(2005)
[Web site]. Safety of RAD001 in combination with cisplatin and etoposide in lung cancer patients
Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma
Cancer Res
(1995)
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines
Oncogene
(1991)
Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling
Oncogene
(2006)
Cited by (0)
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
Copyright © 2008 Elsevier Inc. All rights reserved.